Log in
NASDAQ:PTCT

PTC Therapeutics Competitors

$51.95
-0.01 (-0.02 %)
(As of 10/26/2020 12:00 AM ET)
Add
Compare
Today's Range
$50.91
Now: $51.95
$52.33
50-Day Range
$45.41
MA: $49.25
$54.60
52-Week Range
$30.79
Now: $51.95
$59.89
Volume327,041 shs
Average Volume764,808 shs
Market Capitalization$3.52 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.08

Competitors

PTC Therapeutics (NASDAQ:PTCT) Vs. BMRN, GRFS, ELAN, MYOK, RDY, and SRPT

Should you be buying PTCT stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to PTC Therapeutics, including BioMarin Pharmaceutical (BMRN), GRIFOLS S A/S (GRFS), Elanco Animal Health (ELAN), Myokardia (MYOK), Dr. Reddy's Laboratories (RDY), and Sarepta Therapeutics (SRPT).

PTC Therapeutics (NASDAQ:PTCT) and BioMarin Pharmaceutical (NASDAQ:BMRN) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, profitability, earnings, analyst recommendations, institutional ownership, risk and valuation.

Analyst Ratings

This is a summary of recent recommendations for PTC Therapeutics and BioMarin Pharmaceutical, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
PTC Therapeutics04702.64
BioMarin Pharmaceutical0101302.57

PTC Therapeutics currently has a consensus target price of $61.80, suggesting a potential upside of 18.96%. BioMarin Pharmaceutical has a consensus target price of $119.8750, suggesting a potential upside of 55.92%. Given BioMarin Pharmaceutical's higher possible upside, analysts plainly believe BioMarin Pharmaceutical is more favorable than PTC Therapeutics.

Profitability

This table compares PTC Therapeutics and BioMarin Pharmaceutical's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
PTC Therapeutics-138.67%-67.92%-25.49%
BioMarin Pharmaceutical6.62%4.37%2.88%

Risk & Volatility

PTC Therapeutics has a beta of 1.08, meaning that its stock price is 8% more volatile than the S&P 500. Comparatively, BioMarin Pharmaceutical has a beta of 0.73, meaning that its stock price is 27% less volatile than the S&P 500.

Earnings and Valuation

This table compares PTC Therapeutics and BioMarin Pharmaceutical's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
PTC Therapeutics$306.98 million11.46$-251,580,000.00($3.45)-15.06
BioMarin Pharmaceutical$1.70 billion8.18$-23,850,000.00$0.071,098.29

BioMarin Pharmaceutical has higher revenue and earnings than PTC Therapeutics. PTC Therapeutics is trading at a lower price-to-earnings ratio than BioMarin Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

98.6% of BioMarin Pharmaceutical shares are held by institutional investors. 7.0% of PTC Therapeutics shares are held by insiders. Comparatively, 2.2% of BioMarin Pharmaceutical shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

BioMarin Pharmaceutical beats PTC Therapeutics on 10 of the 14 factors compared between the two stocks.

PTC Therapeutics (NASDAQ:PTCT) and GRIFOLS S A/S (NASDAQ:GRFS) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, profitability, earnings, analyst recommendations, institutional ownership, risk and valuation.

Analyst Ratings

This is a summary of recent recommendations for PTC Therapeutics and GRIFOLS S A/S, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
PTC Therapeutics04702.64
GRIFOLS S A/S04602.60

PTC Therapeutics currently has a consensus target price of $61.80, suggesting a potential upside of 18.96%. Given PTC Therapeutics' stronger consensus rating and higher possible upside, research analysts plainly believe PTC Therapeutics is more favorable than GRIFOLS S A/S.

Profitability

This table compares PTC Therapeutics and GRIFOLS S A/S's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
PTC Therapeutics-138.67%-67.92%-25.49%
GRIFOLS S A/S10.40%10.83%4.68%

Risk & Volatility

PTC Therapeutics has a beta of 1.08, meaning that its stock price is 8% more volatile than the S&P 500. Comparatively, GRIFOLS S A/S has a beta of 0.65, meaning that its stock price is 35% less volatile than the S&P 500.

Earnings and Valuation

This table compares PTC Therapeutics and GRIFOLS S A/S's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
PTC Therapeutics$306.98 million11.46$-251,580,000.00($3.45)-15.06
GRIFOLS S A/S$5.71 billion2.17$700.16 million$1.1715.42

GRIFOLS S A/S has higher revenue and earnings than PTC Therapeutics. PTC Therapeutics is trading at a lower price-to-earnings ratio than GRIFOLS S A/S, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

18.0% of GRIFOLS S A/S shares are held by institutional investors. 7.0% of PTC Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

GRIFOLS S A/S beats PTC Therapeutics on 8 of the 14 factors compared between the two stocks.

PTC Therapeutics (NASDAQ:PTCT) and Elanco Animal Health (NYSE:ELAN) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, profitability, earnings, analyst recommendations, institutional ownership, risk and valuation.

Analyst Ratings

This is a summary of recent recommendations for PTC Therapeutics and Elanco Animal Health, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
PTC Therapeutics04702.64
Elanco Animal Health13702.55

PTC Therapeutics currently has a consensus target price of $61.80, suggesting a potential upside of 18.96%. Elanco Animal Health has a consensus target price of $28.50, suggesting a potential downside of 7.56%. Given PTC Therapeutics' stronger consensus rating and higher possible upside, research analysts plainly believe PTC Therapeutics is more favorable than Elanco Animal Health.

Profitability

This table compares PTC Therapeutics and Elanco Animal Health's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
PTC Therapeutics-138.67%-67.92%-25.49%
Elanco Animal Health-3.63%4.68%3.05%

Risk & Volatility

PTC Therapeutics has a beta of 1.08, meaning that its stock price is 8% more volatile than the S&P 500. Comparatively, Elanco Animal Health has a beta of 1.04, meaning that its stock price is 4% more volatile than the S&P 500.

Earnings and Valuation

This table compares PTC Therapeutics and Elanco Animal Health's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
PTC Therapeutics$306.98 million11.46$-251,580,000.00($3.45)-15.06
Elanco Animal Health$3.07 billion4.00$67.90 million$1.0629.08

Elanco Animal Health has higher revenue and earnings than PTC Therapeutics. PTC Therapeutics is trading at a lower price-to-earnings ratio than Elanco Animal Health, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

98.2% of Elanco Animal Health shares are held by institutional investors. 7.0% of PTC Therapeutics shares are held by insiders. Comparatively, 0.1% of Elanco Animal Health shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

Elanco Animal Health beats PTC Therapeutics on 7 of the 13 factors compared between the two stocks.

PTC Therapeutics (NASDAQ:PTCT) and Myokardia (NASDAQ:MYOK) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, profitability, earnings, analyst recommendations, institutional ownership, risk and valuation.

Analyst Ratings

This is a summary of recent recommendations for PTC Therapeutics and Myokardia, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
PTC Therapeutics04702.64
Myokardia011102.08

PTC Therapeutics currently has a consensus target price of $61.80, suggesting a potential upside of 18.96%. Myokardia has a consensus target price of $207.40, suggesting a potential downside of 7.00%. Given PTC Therapeutics' stronger consensus rating and higher possible upside, research analysts plainly believe PTC Therapeutics is more favorable than Myokardia.

Volatility and Risk

PTC Therapeutics has a beta of 1.08, meaning that its stock price is 8% more volatile than the S&P 500. Comparatively, Myokardia has a beta of 2.07, meaning that its stock price is 107% more volatile than the S&P 500.

Profitability

This table compares PTC Therapeutics and Myokardia's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
PTC Therapeutics-138.67%-67.92%-25.49%
MyokardiaN/A-47.99%-42.42%

Earnings and Valuation

This table compares PTC Therapeutics and Myokardia's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
PTC Therapeutics$306.98 million11.46$-251,580,000.00($3.45)-15.06
Myokardia$33.56 million352.20$-276,210,000.00($4.38)-50.91

PTC Therapeutics has higher revenue and earnings than Myokardia. Myokardia is trading at a lower price-to-earnings ratio than PTC Therapeutics, indicating that it is currently the more affordable of the two stocks.

Summary

PTC Therapeutics beats Myokardia on 8 of the 12 factors compared between the two stocks.

PTC Therapeutics (NASDAQ:PTCT) and Dr. Reddy's Laboratories (NYSE:RDY) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, valuation, earnings, dividends, risk, analyst recommendations and institutional ownership.

Institutional & Insider Ownership

12.8% of Dr. Reddy's Laboratories shares are held by institutional investors. 7.0% of PTC Therapeutics shares are held by insiders. Comparatively, 2.0% of Dr. Reddy's Laboratories shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for PTC Therapeutics and Dr. Reddy's Laboratories, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
PTC Therapeutics04702.64
Dr. Reddy's Laboratories02402.67

PTC Therapeutics presently has a consensus target price of $61.80, suggesting a potential upside of 18.96%. Dr. Reddy's Laboratories has a consensus target price of $53.00, suggesting a potential downside of 20.78%. Given PTC Therapeutics' higher possible upside, equities analysts clearly believe PTC Therapeutics is more favorable than Dr. Reddy's Laboratories.

Risk & Volatility

PTC Therapeutics has a beta of 1.08, meaning that its stock price is 8% more volatile than the S&P 500. Comparatively, Dr. Reddy's Laboratories has a beta of 0.41, meaning that its stock price is 59% less volatile than the S&P 500.

Profitability

This table compares PTC Therapeutics and Dr. Reddy's Laboratories' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
PTC Therapeutics-138.67%-67.92%-25.49%
Dr. Reddy's Laboratories10.26%18.88%12.50%

Earnings & Valuation

This table compares PTC Therapeutics and Dr. Reddy's Laboratories' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
PTC Therapeutics$306.98 million11.46$-251,580,000.00($3.45)-15.06
Dr. Reddy's Laboratories$2.32 billion4.79$259 million$2.7923.98

Dr. Reddy's Laboratories has higher revenue and earnings than PTC Therapeutics. PTC Therapeutics is trading at a lower price-to-earnings ratio than Dr. Reddy's Laboratories, indicating that it is currently the more affordable of the two stocks.

Summary

Dr. Reddy's Laboratories beats PTC Therapeutics on 9 of the 14 factors compared between the two stocks.

PTC Therapeutics (NASDAQ:PTCT) and Sarepta Therapeutics (NASDAQ:SRPT) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, valuation, earnings, dividends, risk, analyst recommendations and institutional ownership.

Institutional & Insider Ownership

92.7% of Sarepta Therapeutics shares are held by institutional investors. 7.0% of PTC Therapeutics shares are held by insiders. Comparatively, 5.9% of Sarepta Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for PTC Therapeutics and Sarepta Therapeutics, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
PTC Therapeutics04702.64
Sarepta Therapeutics022202.92

PTC Therapeutics presently has a consensus target price of $61.80, suggesting a potential upside of 18.96%. Sarepta Therapeutics has a consensus target price of $197.8696, suggesting a potential upside of 42.74%. Given Sarepta Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Sarepta Therapeutics is more favorable than PTC Therapeutics.

Risk & Volatility

PTC Therapeutics has a beta of 1.08, meaning that its stock price is 8% more volatile than the S&P 500. Comparatively, Sarepta Therapeutics has a beta of 1.82, meaning that its stock price is 82% more volatile than the S&P 500.

Profitability

This table compares PTC Therapeutics and Sarepta Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
PTC Therapeutics-138.67%-67.92%-25.49%
Sarepta Therapeutics-117.80%-53.02%-22.67%

Earnings & Valuation

This table compares PTC Therapeutics and Sarepta Therapeutics' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
PTC Therapeutics$306.98 million11.46$-251,580,000.00($3.45)-15.06
Sarepta Therapeutics$380.83 million28.58$-715,080,000.00($9.71)-14.28

PTC Therapeutics has higher earnings, but lower revenue than Sarepta Therapeutics. PTC Therapeutics is trading at a lower price-to-earnings ratio than Sarepta Therapeutics, indicating that it is currently the more affordable of the two stocks.

Summary

Sarepta Therapeutics beats PTC Therapeutics on 10 of the 14 factors compared between the two stocks.


PTC Therapeutics Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
BioMarin Pharmaceutical logo
BMRN
BioMarin Pharmaceutical
2.7$76.88-0.8%$14.06 billion$1.70 billion116.48
GRIFOLS S A/S logo
GRFS
GRIFOLS S A/S
1.0$18.04-2.6%$12.40 billion$5.71 billion20.04Upcoming Earnings
Dividend Cut
Elanco Animal Health logo
ELAN
Elanco Animal Health
2.1$30.83-1.8%$12.30 billion$3.07 billion-123.32Analyst Report
Myokardia logo
MYOK
Myokardia
0.9$223.00-0.0%$11.82 billion$33.56 million-31.36Upcoming Earnings
Dr. Reddy's Laboratories logo
RDY
Dr. Reddy's Laboratories
1.1$66.90-0.6%$11.09 billion$2.32 billion44.01Upcoming Earnings
Sarepta Therapeutics logo
SRPT
Sarepta Therapeutics
1.9$138.62-0.6%$10.88 billion$380.83 million-19.75
Teva Pharmaceutical Industries logo
TEVA
Teva Pharmaceutical Industries
2.3$9.12-2.5%$9.96 billion$16.89 billion3.95
Mirati Therapeutics logo
MRTX
Mirati Therapeutics
1.0$196.68-8.4%$8.76 billion$3.34 million-27.62Upcoming Earnings
Analyst Report
High Trading Volume
Heavy News Reporting
Ascendis Pharma A/S logo
ASND
Ascendis Pharma A/S
1.5$158.61-0.7%$8.44 billion$14.98 million-26.00
Galapagos logo
GLPG
Galapagos
1.3$127.27-0.3%$8.32 billion$1.00 billion81.58Analyst Downgrade
Jazz Pharmaceuticals logo
JAZZ
Jazz Pharmaceuticals
1.9$148.93-0.9%$8.26 billion$2.16 billion64.47Upcoming Earnings
Analyst Report
Heavy News Reporting
Mylan logo
MYL
Mylan
1.8$15.05-4.3%$7.78 billion$11.50 billion28.40Upcoming Earnings
ACADIA Pharmaceuticals logo
ACAD
ACADIA Pharmaceuticals
1.9$44.87-3.8%$6.81 billion$339.08 million-30.52
Ionis Pharmaceuticals logo
IONS
Ionis Pharmaceuticals
1.6$47.01-0.7%$6.57 billion$1.12 billion53.42
Bausch Health Companies logo
BHC
Bausch Health Companies
1.7$17.83-3.0%$6.52 billion$8.60 billion-3.08Upcoming Earnings
Analyst Report
Analyst Revision
Heavy News Reporting
Perrigo logo
PRGO
Perrigo
2.7$44.78-1.9%$6.11 billion$4.84 billion25.74Dividend Announcement
Arrowhead Pharmaceuticals logo
ARWR
Arrowhead Pharmaceuticals
1.2$59.10-0.4%$6.02 billion$168.80 million-236.40
Blueprint Medicines logo
BPMC
Blueprint Medicines
1.3$103.17-1.5%$5.79 billion$66.51 million-13.45Upcoming Earnings
Ultragenyx Pharmaceutical logo
RARE
Ultragenyx Pharmaceutical
1.3$91.25-2.0%$5.53 billion$103.71 million-17.48Heavy News Reporting
United Therapeutics logo
UTHR
United Therapeutics
1.5$123.57-0.6%$5.49 billion$1.45 billion12.69Upcoming Earnings
Emergent Biosolutions logo
EBS
Emergent Biosolutions
1.1$95.29-0.9%$5.04 billion$1.11 billion29.69
BBIO
BridgeBio Pharma
1.4$39.69-0.1%$4.85 billion$40.56 million-13.50
Amicus Therapeutics logo
FOLD
Amicus Therapeutics
1.0$18.75-1.4%$4.85 billion$182.24 million-16.45
Biohaven Pharmaceutical logo
BHVN
Biohaven Pharmaceutical
1.1$77.46-2.0%$4.71 billionN/A-7.02
Arena Pharmaceuticals logo
ARNA
Arena Pharmaceuticals
1.2$85.50-4.9%$4.69 billion$806.43 million-12.52
Allakos logo
ALLK
Allakos
1.1$91.06-1.3%$4.39 billionN/A-38.75Heavy News Reporting
ChemoCentryx logo
CCXI
ChemoCentryx
1.5$53.20-10.5%$4.05 billion$36.13 million-98.52Upcoming Earnings
Heavy News Reporting
Hutchison China MediTech logo
HCM
Hutchison China MediTech
1.4$30.05-2.2%$4.01 billion$204.89 million-37.56Analyst Downgrade
Heavy News Reporting
TPTX
Turning Point Therapeutics
1.5$93.64-9.5%$3.95 billionN/A-25.17Upcoming Earnings
Analyst Report
High Trading Volume
Heavy News Reporting
Reata Pharmaceuticals logo
RETA
Reata Pharmaceuticals
1.4$114.63-2.3%$3.85 billion$26.52 million-10.68
Insmed logo
INSM
Insmed
1.1$36.89-0.3%$3.74 billion$136.47 million-13.92Upcoming Earnings
SDGR
Schrödinger
1.7$58.01-4.5%$3.67 billion$85.54 million0.00Analyst Upgrade
FibroGen logo
FGEN
FibroGen
1.5$39.96-6.6%$3.61 billion$256.58 million-11.32Analyst Report
Unusual Options Activity
Heavy News Reporting
Sage Therapeutics logo
SAGE
Sage Therapeutics
1.4$68.50-4.4%$3.56 billion$6.87 million-5.81
Deciphera Pharmaceuticals logo
DCPH
Deciphera Pharmaceuticals
1.3$62.73-2.1%$3.54 billion$25 million-12.18Upcoming Earnings
Heavy News Reporting
Global Blood Therapeutics logo
GBT
Global Blood Therapeutics
1.6$56.53-0.3%$3.47 billion$2.11 million-11.98
Principia Biopharma logo
PRNB
Principia Biopharma
1.1$100.05-0.0%$3.32 billion$35.16 million-41.51Upcoming Earnings
TG Therapeutics logo
TGTX
TG Therapeutics
1.7$26.07-3.6%$3.30 billion$150,000.00-12.53
Nektar Therapeutics logo
NKTR
Nektar Therapeutics
1.6$16.97-3.4%$3.04 billion$114.62 million-6.98
Opko Health logo
OPK
Opko Health
2.4$4.31-0.2%$2.89 billion$901.90 million-13.06Upcoming Earnings
GW Pharmaceuticals logo
GWPH
GW Pharmaceuticals
1.8$92.13-3.1%$2.86 billion$311.33 million-50.07Upcoming Earnings
Analyst Upgrade
Heavy News Reporting
Eidos Therapeutics logo
EIDX
Eidos Therapeutics
1.1$73.27-0.0%$2.83 billion$26.69 million-43.61Upcoming Earnings
Apellis Pharmaceuticals logo
APLS
Apellis Pharmaceuticals
1.5$35.86-0.2%$2.71 billionN/A-5.33Upcoming Earnings
Axsome Therapeutics logo
AXSM
Axsome Therapeutics
1.6$68.69-3.9%$2.66 billionN/A-26.02
Agios Pharmaceuticals logo
AGIO
Agios Pharmaceuticals
1.6$37.48-1.5%$2.63 billion$117.91 million-7.06
Alkermes logo
ALKS
Alkermes
1.7$15.91-3.0%$2.61 billion$1.17 billion-19.89Upcoming Earnings
IMAB
I-Mab
1.0$41.19-1.3%$2.35 billion$4.31 million-1.43High Trading Volume
Pacira BioSciences logo
PCRX
Pacira BioSciences
1.4$53.82-3.1%$2.30 billion$421.03 million-215.28Upcoming Earnings
Taro Pharmaceutical Industries logo
TARO
Taro Pharmaceutical Industries
1.4$60.00-0.0%$2.30 billion$644.77 million-8.92Upcoming Earnings
Seres Therapeutics logo
MCRB
Seres Therapeutics
1.6$29.84-1.1%$2.28 billion$34.51 million-28.69Upcoming Earnings
Analyst Report
Heavy News Reporting
This page was last updated on 10/27/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.